| Ytd | -44.64% | |
| 1y | -46.47% |
| Open | 1.38 | Prev Close | 1.38 | Low | 1.27 | High | 1.41 | Mkt Cap | 79.90M |
| Vol | 1.25M | Avg Vol | 1.28M | EPS | 0.24 | P/E | 5.75 | Forward P/E | -0.83 |
| Beta | 1.49 | Short Ratio | 2.08 | Inst. Own | 23.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 2.40 | 200-d Avg | 2.40 | 1yr Est | 5.00 |
SPRO News
Spero Therapeutics is initiated with a "Buy" rating, driven by its strategic pivot to immunology and
Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular sess
Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-license
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater Chin
CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clin
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater Chin
CAMBRIDGE, Mass. and SAN FRANCISCO and SUZHOU, China, July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therap
LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Comp
Spero Therapeutics, Inc. and partner GSK receive FDA approval for Utebzi, the first oral carbapenem
GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding
Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today a
FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late
CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK
https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adult
New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), includ
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clini
Spero Therapeutics (NASDAQ: SPRO - Get Free Report) and Mereo BioPharma Group (NASDAQ: MREO - Get Fr
CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clin
CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clin
Spero Therapeutics' lead asset is an oral carbapenem tebipenem for cUTI. This asset achieved Phase 3
Shares of Spero Therapeutics, Inc. (NASDAQ: SPRO - Get Free Report) crossed below its two hundred da
CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clini
CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clin
Results from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clin
On Wednesday, 311 stocks hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
On Tuesday, 951 companies hit new 52-week lows.
Monday's session saw 84 companies set new 52-week lows.
On Monday, 149 companies reached new 52-week lows.
On Wednesday, 216 stocks hit new 52-week lows.
Tuesday's session saw 211 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
On Friday, 431 companies hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
On Wednesday, 348 companies hit new 52-week lows.
On Friday, 209 companies set new 52-week lows.
On Thursday, 105 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Celsius Holdings (NASDAQ:CELH) is estimated to report quar
During Wednesday's morning trading, 254 companies set new 52-week highs.